Medtronic Draws Fresh Analyst Conviction as Hugo Clears General Surgery Hurdle
Published on 11/21/2026 at 15:02 | Editorial boerse-global.deMedtronic's robot-assisted surgical platform Hugo secured a broader US green light on 17 November, and the regulatory win has coincided with a wave of bullish recalibration on Wall Street. The FDA cleared Hugo for general surgery procedures, covering all operations in the upper abdomen and a defined set of lower-abdomen interventions.
The label expansion landed the same day Piper Sandler's Matt O'Brien moved Medtronic from "Neutral" to "Overweight" and lifted his price target to $120 from $85. Two days earlier, on 16 November, the medical-device maker had announced plans to acquire Contego Medical for $380 million, with further contingent payments possible after closing. The deal would broaden Medtronic's portfolio with technologies for carotid artery disease and peripheral thrombectomy. Management expects to complete the transaction subject to customary conditions and anticipates a modest dilution to adjusted earnings per share across fiscal 2027 and fiscal 2028.
Thursday brought a further round of target revisions. Leerink Partners' Mike Kratky raised his price target to $117 from $111 while reiterating an "Outperform" rating. A second research house also lifted its target to $109 from $99 and kept its buy recommendation intact. The shares slipped 0.6% in the prior session, closing at €91.16.
Should investors sell immediately? Or is it worth buying Medtronic?
Attention now turns to the company's fiscal second-quarter report for the 2027 financial year, scheduled for 24 November 2026.
Ad
Medtronic Stock: New Analysis - 21 November
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
